tablet glp 1 for weight loss Novo Nordisk launches Wegovy weight-loss pill in US, triggering price war | Pharmaceuticals industry Feel fuller The First Oral GLP-1 Pill

Why We Do Science in the First Place This story highlights that scientific progress often begins with curiosity rather than clear application

The conflicting safety signal One real-world evidence study found that patients receiving GLP-1 receptor agonists had higher risks of certain autoimmune conditions, including ulcerative colitis, rheumatoid arthritis, autoimmune thyroiditis, ankylosing spondylitis, and psoriasis, compared to those on DPP-4 inhibitors

Journal of Clinical Endocrinology and Metabolism 2020

To view or add a comment, sign in 2,835 followers

2024;150(Suppl_1):A4113997-A4113997

doi:10.1056/NEJMoa1509225 299